ferrosig injection iron 100mg/2ml (as polymaltose) injection ampoule
sigma company limited - iron polymaltose, quantity: 318 mg (equivalent: iron, qty 100 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - indications as at 8 april 2002: for the treatment of iron deficiency anaemia in the following circumstances: * when oral therapy is contraindicated. * when enteric absorption of iron is defective. * when patient non-compliance or persistent gastrointestinal intolerance makes oral therapy impractical.
sigma hp partial trochlea - patellofemoral joint prosthesis
johnson & johnson medical pty ltd t/a depuy synthes -
mizosin tablet 2mg
duopharma (m) sdn. bhd. - sigma-prazosin hydrochloride -
mizosin tablet 1mg
duopharma (m) sdn. bhd. - sigma-prazosin hydrochloride -
carnitor oral single dose 1g solution
logixx pharma solutions ltd - l-carnitine - oral solution - 100mg/1ml
carnitor 1g/5ml solution for injection ampoules
logixx pharma solutions ltd - l-carnitine - solution for injection - 200mg/1ml
carnitor 1g chewable tablets
logixx pharma solutions ltd - l-carnitine - chewable tablet - 1gram
flucytosine capsule
sigmapharm laboratories, llc - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules, usp are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules, usp should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules, usp (see microbiology). flucytosine capsules, usp should not be used in patients with a known hypersensitivity to the drug.
griseofulvin tablet
sigmapharm laboratories, llc - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - griseofulvin is indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy, hair and nails, namely: tinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi: epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note: prior to therapy, a dermatophyte should be identified as responsible for the infection. prior to initiating treatment, appropriate specimens for laboratory testing (koh preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis. griseofulvin is not effective in the following: bacterial infections candidiasis (moniliasis) histoplasmosis actinomycosis spo
ultramicrosize griseofulvin tablet
sigmapharm laboratories, llc - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - ultramicrosize griseofulvin tablets, usp are indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: trichophyton rubrum, trichophyton tonsurans, trichophyton mentagrophytes, trichophyton interdigitalis, trichophyton verrucosum, trichophyton megnini, trichophyton gallinae, trichophyton crateriform, trichophyton sulphureum, trichophyton schoenleini, microsporum audouini, microsporum canis, microsporum gypseum and epidermophyton floccosum . note: prior to therapy, the type of fungi responsible for the infection should be identified. the use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. griseofulvin is not effective in